Disease · MONDO_0021350

neoplasm of thorax

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. neoplasm of thorax. Diseases, record MONDO_0021350. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021350

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: neoplasm of thorax; Open Targets
Open Targets ID: MONDO_0021350; Open Targets
Other names: neoplasm of the thorax, neoplasm of thoracic segment of trunk, thoracic neoplasm, thoracic segment of trunk neoplasm, thoracic segment of trunk neoplasm (disease), thoracic segment of trunk tumor, thoracic segment of trunk tumour, thoracic tumor, thoracic tumour, tumor of the thorax, tumor of thoracic segment of trunk, tumor of thorax, tumour of the thorax, tumour of thoracic segment of trunk, tumour of thorax; Open Targets
NCI Thesaurus: C3406; NCI Thesaurus
Highest stage of its drugs: Phase 1, for 5 of its 6 drugs, from ClinicalTrials.gov; Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
PEMETREXED	CHEMBL225072	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
SOTORASIB	CHEMBL4535757	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
METFORMIN	CHEMBL1431	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets71

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
COXFA4	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Early phase 1	https://conductscience.org/library/genes/4697	Drugs and targets
COXFA4L2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Early phase 1	https://conductscience.org/library/genes/56901	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 1	https://conductscience.org/library/genes/1719	Drugs and targets
GART	Trifunctional purine biosynthetic protein adenosine-3	1	GAR transformylase inhibitor	Phase 1	https://conductscience.org/library/genes/2618	Drugs and targets
GPD2	Glycerol-3-phosphate dehydrogenase, mitochondrial	1	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor	Early phase 1	https://conductscience.org/library/genes/2820	Drugs and targets
KRAS	GTPase KRas	1	GTPase KRas inhibitor	Phase 1	https://conductscience.org/library/genes/3845	Drugs and targets
MT-ND1	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Early phase 1	https://conductscience.org/library/genes/4535	Drugs and targets
MT-ND2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Early phase 1	https://conductscience.org/library/genes/4536	Drugs and targets
MT-ND3	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Early phase 1	https://conductscience.org/library/genes/4537	Drugs and targets
MT-ND4	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Early phase 1	https://conductscience.org/library/genes/4538	Drugs and targets

1 to 10 of 71

See all 71 targets

Trials2

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03477162	Metformin Pharmacology in Human Cancers: A Proof of Principle Study	Early phase 1	18	2023-10-03	Thoracic Neoplasm	METFORMIN	Its record names the disease	ClinicalTrials.gov
NCT06333951	Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).	Phase 1	49		Thoracic Tumors, Non-small Cell Lung Cancer	CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB, PEMETREXED, SOTORASIB	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Metformin vs Control: deaths from any cause	0 of 14	0 of 1	15	NCT03477162	Trial comparisons
Metformin vs Control: serious adverse events	0 of 14	0 of 1	15	NCT03477162	Trial comparisons

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0021350

GET https://conductscience.org/api/diseases/v1/MONDO_0021350/targets?page=2

API reference For AI assistants